Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs

Abstract

New CRC treatments have increased both regimen choice and expenditures. New regimens have primarily increased expenditures through direct treatment costs; we observed no offsetting expenditure reductions.